First-in-human Trial of DS-2243a in Participants with Advanced Solid Tumors

2024-512058-11-00 Protocol DS2243-054 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 9 Apr 2025 · Status Ongoing, recruiting · 3 EU/EEA countries · 3 sites · Protocol DS2243-054

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 150
Countries 3
Sites 3

Advanced Solid Tumor

Key facts

Sponsor
Daiichi Sankyo Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
9 Apr 2025 → ongoing
Decision date (initial)
2025-02-10
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-512058-11-00
ClinicalTrials.gov
NCT06644755

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced Solid Tumor

VersionLevelCodeTermSystem organ class
21.1 LLT 10065252 Solid tumor 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Daiichi Sankyo Inc.

Sponsor organisation
Daiichi Sankyo Inc.
Address
211 Mount Airy Road
City
Basking Ridge
Postcode
07920-2311
Country
United States

Scientific contact point

Organisation
Daiichi Sankyo Inc.
Contact name
Clinical Trial Office

Public contact point

Organisation
Daiichi Sankyo Inc.
Contact name
Clinical Trial Office

Locations

3 EU/EEA countries · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ongoing, recruiting 8 1
France Ongoing, recruiting 28 1
Netherlands Ongoing, recruiting 9 1
Rest of world
United States, Korea, Republic of
105

Investigational sites

Belgium

1 site · Ongoing, recruiting
UZ Leuven
Medical oncology, Herestraat 49, 3000, Leuven

France

1 site · Ongoing, recruiting
Centre Leon Berard
Cancérologie médicale, 28 Rue Laennec, 69008, Lyon

Netherlands

1 site · Ongoing, recruiting
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Clinical Research Unit, Department of Medical Oncology, Plesmanlaan 121, 1066 CX, Amsterdam

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2025-04-17 2025-04-22
France 2025-04-09 2025-06-25
Netherlands 2025-06-02 2025-07-08

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-22 Belgium Acceptable with conditions
2025-02-03
2025-02-05
2 SUBSTANTIAL MODIFICATION SM-1 2025-06-26 Belgium Acceptable
2025-08-21
2025-08-21
3 NON SUBSTANTIAL MODIFICATION NSM-1 2025-10-10 Belgium Acceptable
2025-08-21
2025-10-10